US2688018A - Method of preparing alkaline earth metal salts of 1-leucovorin - Google Patents

Method of preparing alkaline earth metal salts of 1-leucovorin Download PDF

Info

Publication number
US2688018A
US2688018A US296249A US29624952A US2688018A US 2688018 A US2688018 A US 2688018A US 296249 A US296249 A US 296249A US 29624952 A US29624952 A US 29624952A US 2688018 A US2688018 A US 2688018A
Authority
US
United States
Prior art keywords
formyl
alkaline earth
earth metal
leucovorin
tetrahydropteroyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US296249A
Inventor
Donna B Cosulich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Priority to US296249A priority Critical patent/US2688018A/en
Application granted granted Critical
Publication of US2688018A publication Critical patent/US2688018A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

Definitions

  • This invention relates to new organic compounds having increased biological activity. More particularly; it relates to-formyl-Z-5,6,7,8- tetrahydropteroyl-L(+) -glutamic acid and salts 4. Claims. (Cl. 260-2515) rated; This materialwas' recryta -ll-ize'd. from water fourtimes to constant rotation I This th 5 Its solubility in water is only about 2%.
  • the biologically active ZL-isomer is desig- A mixture f 885 parts f the calcium Salt of mated 5-formyl-dl-5,6,'7,8-tetrahydropteroyl-L(+) -glu-
  • the precipitate is filtered, ference in solubility could be obtained by use of a 50 washed and dried to g 0-445 parts of strontium calcium or strontium salt in essentially aqueous 5-f0rmy1-dZ-5,6, y D 0l/ glumedium to allow separation.
  • calcium tamate This is reprecipitated by dissolving in dZ-leucovorin prepared in the usual manner was water and adding ethanol. Finally, the material soluble in water to the extent of 30-40%. On was dissolved in two parts of Water and cooled standing and cooling, calcium Z-leucovorin sepaseveral days. The crystalline salt is separated by decantation of the liquor and dissolved in 2 parts of water.
  • the solution is treated with one part by volume of ethanol and cooled. After isolation, the precipitate weighs 0.16 parts of strontium 5-formyl-Z-5,6,'7,8-tetrahydropteroyl-L(+) glutamate,- which is more active for Leuco'nostoc citrovorum than the starting material.
  • a method of preparing 5iormyl-Z-5,6,7,8- tetrahydropteroyl-L(+)-glutamic acid which comprises forming an alkaline earth metal salt of the group consisting of calcium and strontium salts of 5-formyl-dZ-5,6,'7,8-tetrahydropteroy1- L(+) -glutamic acid, allowingthe more insoluble 5-formyl-2-5,6,7,8-tetrahydropteroyl -L(+) glutamic acid cationic salt to precipitate, separating said precipitate, removing said alkaline earth metal salt radical and recovering said compound therefrom.
  • a method of resolving 5-formyl-dl-5,6,'7,8- tetrahydropteryl-L(+) -glutamic acid which comprises forming an alkaline earth metal salt of the group consisting of calcium and strontium 4 salts of the all compound, allowing the more insoluble 5-formyl Z 5,6,7,8 tetrahydropteroyl- L(+)g1utamic acid salt to precipitate, separating said precipitate and removing said alkaline earth metal salt radicals from the separated isomers.
  • a method of preparing calcium 5-formyl-l- 5,6,7,8-tetrahydropteroyl-L(+) -glutamate which comprises forming a calcium salt of 5-formyl-dl- 5,6,7,B-tetrahydropteroyl-L(-1-) -glutamic acid, allowing the more insoluble calcium 5-formy1-l- 5,6,7 ,8-tetrahydropteroyl-L(+) -glutamate to precipitate and recovering said product therefrom.
  • a method of preparing strontium fi-formyl- Z-5,6,7,8 tetrahydropteroyl L(+) glutamate which comprises forming a stronium salt of 5-formyl-dl-5,6,7,8-tetrahydropteroyl-L(+) -glutamic acid, allowing the more insoluble strontium 5-formyl-Z-5,6,7,8-tetrahydropteroyl -L(+) glutamate to precipitate and recovering said product therefrom.

Description

Patented Aug. 31, 1954 METHOD OF PREPARING EARTH- METAL SALTS OF l-LEUCOVORINf Donna R. Cosulich, Plainfield, N. .L, assignor to American C'yanamid Company, New York,.N. 13.,
acorporation ofMa'ine NolDrawi'ng. Application June 28, 1952,. Serial No. 296,249
This invention relates to new organic compounds having increased biological activity. More particularly; it relates to-formyl-Z-5,6,7,8- tetrahydropteroyl-L(+) -glutamic acid and salts 4. Claims. (Cl. 260-2515) rated; This materialwas' recryta -ll-ize'd. from water fourtimes to constant rotation I This th 5 Its solubility in water is only about 2%.
In t past 5-formy}.5 6 7 8 tetrahydropteroy1 isomer is approximately twice as active for Leuglutamic acid has been described as ynthetic COTLOS'IfOC CitTO'UOTU/In as is the synthetic mixcitrovorum factor, folinic acid-SF, leucovorin, etc. tule (dZ-1e11C0V0Iin)- (Welch et al., Pharmacological Reviews 3, No. 4, The cationic a t of v0r an b pr 376-377 (1951)). It has been used clinically for 10 cipitatcd from substantially aq us s ution in controlling the toxicity of aminopterin and other which the concentration of s t s fr m 3% c antifclic acid compounds, and as a hematopoietic about The 0f the desired $31113, being drug The product as originally prepared ynmuch less soluble than the mixture, separates thetically had acomparatively low activity which out first and can be recovered by filtrationhas since been increased by treatment of the Should the p d OV0 itself be desynthetic product with alkali and other methods. sired, it can be Obtained y treating the Salt W t I have now found, however, that the synthetic a mineral acidproduct is a diasteareoisomeric mixture of the The following examples illustrate in deta l the and ZL f rm and t when t l-form is preparation of representative cationic salts of separated from the isomeric mixture it has an l-leucovolinactivity about twice as great as that of the mix- Example 1 ture. The biologically active ZL-isomer is desig- A mixture f 885 parts f the calcium Salt of mated 5-formyl-dl-5,6,'7,8-tetrahydropteroyl-L(+) -glu- The compound lcuccvorin has the fcllcwmg tamic acid (rotation about [a] =|14) in 885 Structural formula! parts by volume of water is warmed to 50 C. to
H dissolve. On cooling, 9.4 parts of calcium 5-forg i myl-l-5,6,7,8-tetrahydropteroyl-L(+) -glutamate O H 7 (rotation [ozIl about +2") is obtained. By furgQ 5 3N ther treatment of the mother liquor 12.4 parts 6 N 4 more of this product (rotation about +2) is isouoom-on-nfi 1 I OH By recrystallization of this material from water HO O I CH0 four times in 5-10% concentration pure calcium 5-formyl-l-5,6,7,8-tetrahydropteroyl -L(+) glu- Where the carbon atoms marked with an asterisk tamate with a constant rotation [a] =15.2 is are optically active. In separating a mixture obtained. The biological activity as measured of optical isomers into its components in the case against Leuconostoc citro'uorum is approximately of acidic substances the usual procedure is to predouble the unfractionated synthetic dZ-mixture. pare a salt with an optically active base, using The solubility of the uniractionated mixture in alkaloids such as brucine, strychnine, etc. and 40 water is approximately 30% to 40%, from which fractionally crystallizing. Since Solubility difiercalcium Z-leucovorin will separate. Its solubility ences are often obtained in this way. However, in in water is about 2%. preparing a pharmaceutical substance such highly Example 2 toxic materials are very undesirable as contamim 5 To 0.41 parts of 5-formyl-dl-5,6,7,8-tetrahydro- Surprisingly, it was found that the calcium or p y -g111tami0 acid in Parts O Water strontium salt of l-leucovorin was much less solis added sodium hydroxide to pH 7.5, 0.21 parts uble than the mixture of calcium or strontium of strontium chloride hexahydrate and parts dl-leucovorin. It is unusual that enough difby volume of ethanol. The precipitate is filtered, ference in solubility could be obtained by use of a 50 washed and dried to g 0-445 parts of strontium calcium or strontium salt in essentially aqueous 5-f0rmy1-dZ-5,6, y D 0l/ glumedium to allow separation. However, calcium tamate. This is reprecipitated by dissolving in dZ-leucovorin prepared in the usual manner was water and adding ethanol. Finally, the material soluble in water to the extent of 30-40%. On was dissolved in two parts of Water and cooled standing and cooling, calcium Z-leucovorin sepaseveral days. The crystalline salt is separated by decantation of the liquor and dissolved in 2 parts of water. The solution is treated with one part by volume of ethanol and cooled. After isolation, the precipitate weighs 0.16 parts of strontium 5-formyl-Z-5,6,'7,8-tetrahydropteroyl-L(+) glutamate,- which is more active for Leuco'nostoc citrovorum than the starting material.
I claim:
1. A method of preparing 5iormyl-Z-5,6,7,8- tetrahydropteroyl-L(+)-glutamic acid which comprises forming an alkaline earth metal salt of the group consisting of calcium and strontium salts of 5-formyl-dZ-5,6,'7,8-tetrahydropteroy1- L(+) -glutamic acid, allowingthe more insoluble 5-formyl-2-5,6,7,8-tetrahydropteroyl -L(+) glutamic acid cationic salt to precipitate, separating said precipitate, removing said alkaline earth metal salt radical and recovering said compound therefrom.
2. A method of resolving 5-formyl-dl-5,6,'7,8- tetrahydropteryl-L(+) -glutamic acid which comprises forming an alkaline earth metal salt of the group consisting of calcium and strontium 4 salts of the all compound, allowing the more insoluble 5-formyl Z 5,6,7,8 tetrahydropteroyl- L(+)g1utamic acid salt to precipitate, separating said precipitate and removing said alkaline earth metal salt radicals from the separated isomers.
3. A method of preparing calcium 5-formyl-l- 5,6,7,8-tetrahydropteroyl-L(+) -glutamate which comprises forming a calcium salt of 5-formyl-dl- 5,6,7,B-tetrahydropteroyl-L(-1-) -glutamic acid, allowing the more insoluble calcium 5-formy1-l- 5,6,7 ,8-tetrahydropteroyl-L(+) -glutamate to precipitate and recovering said product therefrom.
4. A method of preparing strontium fi-formyl- Z-5,6,7,8 tetrahydropteroyl L(+) glutamate which comprises forming a stronium salt of 5-formyl-dl-5,6,7,8-tetrahydropteroyl-L(+) -glutamic acid, allowing the more insoluble strontium 5-formyl-Z-5,6,7,8-tetrahydropteroyl -L(+) glutamate to precipitate and recovering said product therefrom.
No references cited.

Claims (1)

1. A METHOD OF PREPARING 5-FORMYL-L-5,6,7,8TETRAHYDROPTEROYL-L(+)-GLUATAMIC ACID WHICH COMPRISES FORMING AN ALKALINE EARTH METAL SALT OF THE GROUP CONSISTING OF CALIUM AND STRONTIUM SALTS OF 5-FORMYL-DL-5,6,7,8-TETRAHYDROPTEROYLL(+)-GLUTAMIC ACID, ALLOWING THE MORE INSOLUBLE 5-FORMYL-L-5,6,7,8-TETRAHYDROPTEROYL-L(+)- GLUTAMIC ACID CATIONIC SALT TO PRECIPITATE, SEPARATING SAID PRECIPITATE, REMOVING SAID ALKALINE EARTH METAL SALT RADICAL AND RECOVERING SAID COMPOUND THEREFROM.
US296249A 1952-06-28 1952-06-28 Method of preparing alkaline earth metal salts of 1-leucovorin Expired - Lifetime US2688018A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US296249A US2688018A (en) 1952-06-28 1952-06-28 Method of preparing alkaline earth metal salts of 1-leucovorin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US296249A US2688018A (en) 1952-06-28 1952-06-28 Method of preparing alkaline earth metal salts of 1-leucovorin

Publications (1)

Publication Number Publication Date
US2688018A true US2688018A (en) 1954-08-31

Family

ID=23141232

Family Applications (1)

Application Number Title Priority Date Filing Date
US296249A Expired - Lifetime US2688018A (en) 1952-06-28 1952-06-28 Method of preparing alkaline earth metal salts of 1-leucovorin

Country Status (1)

Country Link
US (1) US2688018A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862132A (en) * 1971-03-13 1975-01-21 Ajinomoto Kk Optical resolution of dl-2-pyrrolidone-5-carboxylic acid
WO1988008844A1 (en) * 1987-05-15 1988-11-17 Eprova Ag Process for separation of folinic acids
EP0348641A2 (en) * 1988-06-29 1990-01-03 EPROVA Aktiengesellschaft Process for the preparation of tetrahydrofolates
EP0367902A2 (en) * 1988-11-11 1990-05-16 EPROVA Aktiengesellschaft Process for the separation of folinic acid
EP0455013A1 (en) * 1990-04-12 1991-11-06 Cerbios-Pharma S.A. Ammoniumsalts of N(5)-methyl-5,6,7,8-tetrahydrofolic acid
US5173488A (en) * 1989-08-21 1992-12-22 American Cyanamid Company Stable injectable pharmaceutical formulation for folic acid and leucovorin salts and method
EP0535710A1 (en) * 1991-10-04 1993-04-07 Sapec S.A. Fine Chemicals Process for the preparation of alkaline earth metal salts of (6R)-N(10)-formyl-5,6,7,8-tetrahydrofolic acid
WO1993017022A1 (en) * 1992-02-20 1993-09-02 Bracco S.P.A. Process for separating stereoisomers of folinic acid
US5599931A (en) * 1992-02-20 1997-02-04 Bracco S.P.A. Process for separating stereoisomers of folinic acid
WO2000023448A1 (en) * 1998-10-22 2000-04-27 Moheno Phillip B B Novel pterin antineoplastic agents
US6500829B1 (en) * 1986-09-03 2002-12-31 University Of Strathclyde Substantially pure diastereoisomers of tetrahydrofolate derivatives
WO2009046581A1 (en) * 2007-10-11 2009-04-16 Nanjing Rally Biochemical Inc A process for resolution of (6r,s)-5-formyltetrahydrofolic acid and its salification

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862132A (en) * 1971-03-13 1975-01-21 Ajinomoto Kk Optical resolution of dl-2-pyrrolidone-5-carboxylic acid
US6500829B1 (en) * 1986-09-03 2002-12-31 University Of Strathclyde Substantially pure diastereoisomers of tetrahydrofolate derivatives
WO1988008844A1 (en) * 1987-05-15 1988-11-17 Eprova Ag Process for separation of folinic acids
EP0293029A1 (en) * 1987-05-15 1988-11-30 EPROVA Aktiengesellschaft Process for the preparation of folic acid
US5134235A (en) * 1987-05-15 1992-07-28 Eprova A.G. Process for separating folinic acid
EP0348641A3 (en) * 1988-06-29 1991-04-24 EPROVA Aktiengesellschaft Process for the preparation of tetrahydrofolates
EP0348641A2 (en) * 1988-06-29 1990-01-03 EPROVA Aktiengesellschaft Process for the preparation of tetrahydrofolates
US5006655A (en) * 1988-06-29 1991-04-09 Eprova Ag Process for the preparation of tetrahydrofolates
EP0367902A3 (en) * 1988-11-11 1991-04-03 EPROVA Aktiengesellschaft Process for the separation of folinic acid
US5010194A (en) * 1988-11-11 1991-04-23 Eprova Ag Method for the resolution of folinic acid
EP0367902A2 (en) * 1988-11-11 1990-05-16 EPROVA Aktiengesellschaft Process for the separation of folinic acid
US5173488A (en) * 1989-08-21 1992-12-22 American Cyanamid Company Stable injectable pharmaceutical formulation for folic acid and leucovorin salts and method
EP0455013A1 (en) * 1990-04-12 1991-11-06 Cerbios-Pharma S.A. Ammoniumsalts of N(5)-methyl-5,6,7,8-tetrahydrofolic acid
US5194611A (en) * 1990-04-12 1993-03-16 Sapec S.A. Fine Chemicals Separation technique for a mixture of (6RS)-diastereoisomers of an ammonium salt of N5 -methyl-5,6,7,8-tetrahydrofolic acid into single (6R) and (6S)-diastereoisomers
EP0535710A1 (en) * 1991-10-04 1993-04-07 Sapec S.A. Fine Chemicals Process for the preparation of alkaline earth metal salts of (6R)-N(10)-formyl-5,6,7,8-tetrahydrofolic acid
WO1993017022A1 (en) * 1992-02-20 1993-09-02 Bracco S.P.A. Process for separating stereoisomers of folinic acid
US5599931A (en) * 1992-02-20 1997-02-04 Bracco S.P.A. Process for separating stereoisomers of folinic acid
WO2000023448A1 (en) * 1998-10-22 2000-04-27 Moheno Phillip B B Novel pterin antineoplastic agents
US6358953B1 (en) 1998-10-22 2002-03-19 Phillip B. B. Moheno Pterin antineoplastic agents
WO2009046581A1 (en) * 2007-10-11 2009-04-16 Nanjing Rally Biochemical Inc A process for resolution of (6r,s)-5-formyltetrahydrofolic acid and its salification

Similar Documents

Publication Publication Date Title
US2688018A (en) Method of preparing alkaline earth metal salts of 1-leucovorin
CA2121351C (en) The resolution of 5-methyltetrahydrofolic acid
PT87355B (en) PROCESS FOR THE PRODUCTION OF FOLINIC ACID
NZ231193A (en) Method for the resolution of (6r,s) folinates
US2404319A (en) Butanolamine salts of theophylline
US3936495A (en) Purification process
SU517587A1 (en) Method for preparing 2-oxphenylurea derivatives
US3579530A (en) Process for the resolution of racemic tetramisole
US4500711A (en) Synthesis of leucovorin
US3381031A (en) Resolution of racemic amino acids
US2625567A (en) 1-benzyloxy-2-alkylaminoindanes
US3085110A (en) Resolution of n-d-and n-1-sec-butylcyclo-hexylamine by methyl hydrogen di-benzoyl-d tartrate
US1867332A (en) Ethanol-amine salts of theophylline and process of making them
US2397903A (en) Methylene-bis-2 hydroxy-3 naphthoates
US2915555A (en) Preparation of crystalline oxytetracycline salts
US2580195A (en) Method of purifying 4-aminosalicylic acid
US2398706A (en) Riboflavin derivatives and process of preparing the same
US2265217A (en) D - lysergic acid -
US3755373A (en) Salts of 1-ephedrine and a d (-)-1-alpha-azidofluorophenylacetic acid
US2553515A (en) N-(p-arsenoso-benzyl)-urea
US2715141A (en) Optically active isopropyl arterenol
US3098854A (en) Acid addition salts of basically substituted flavones and preparation thereof
US2578761A (en) Alkanolamine salts of sulfaquinoxaline
US2899422A (en) Purification of chlortetracycline
US3912738A (en) Isomers of N,N{40 -bis-{8 (1-formamido-2,2,2-trichloro)-ethyl{9 -piperazine and method of isolating the same